Insulet Operating Income Over Time
| PODD Stock | USD 242.74 1.92 0.80% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Insulet Performance and Insulet Correlation. Will Health Care Equipment & Supplies sector continue expanding? Could Insulet diversify its offerings? Factors like these will boost the valuation of Insulet. Anticipated expansion of Insulet directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Insulet data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 0.148 | Earnings Share 3.42 | Revenue Per Share | Quarterly Revenue Growth 0.299 | Return On Assets |
Understanding Insulet requires distinguishing between market price and book value, where the latter reflects Insulet's accounting equity. The concept of intrinsic value - what Insulet's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Insulet's price substantially above or below its fundamental value.
It's important to distinguish between Insulet's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Insulet should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Insulet's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Operating Income Analysis
Compare Insulet and related stocks such as DexCom Inc, STERIS plc, and Koninklijke Philips Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DXCM | (4 M) | (44.8 M) | (55.7 M) | (28.9 M) | (21.5 M) | (57.1 M) | (63.9 M) | (42.5 M) | (186.3 M) | 142.3 M | 299.5 M | 265.8 M | 391.2 M | 597.7 M | 600 M | 911.8 M | 957.4 M |
| STE | 200 K | 222.3 M | 242.8 M | 206.8 M | 227.2 M | 212.9 M | 226.2 M | 399.9 M | 411 M | 537 M | 548.4 M | 477.8 M | 791.1 M | 836.1 M | 866.6 M | 996.6 M | 1 B |
| PHG | 868.3 M | (269 M) | 1 B | 2 B | 486 M | 992 M | 1.9 B | 1.5 B | 1.7 B | 1.4 B | 1.3 B | 553 M | (1.5 B) | (115 M) | 529 M | 1.4 B | 850.1 M |
| ZBH | 211 M | 1 B | 1 B | 1 B | 1 B | 467.3 M | 821.1 M | 799.3 M | 33.8 M | 1.1 B | 83.1 M | 860.3 M | 696.3 M | 1.3 B | 1.3 B | 1.4 B | 861 M |
| BIIB | (32.9 M) | 1.7 B | 1.8 B | 2.5 B | 4 B | 4.9 B | 5.2 B | 5.3 B | 5.9 B | 7 B | 4.6 B | 2.8 B | 2.9 B | 2.1 B | 2.5 B | 1.9 B | 1.6 B |
| LH | 313.9 M | 948.4 M | 1 B | 990.9 M | 910.4 M | 1 B | 1.3 B | 1.4 B | 1.3 B | 1.3 B | 2.4 B | 3 B | 1.4 B | 725.6 M | 1.1 B | 1.2 B | 814 M |
| WAT | 56.4 M | 528.6 M | 511.5 M | 517.3 M | 517.9 M | 567.5 M | 625 M | 662.2 M | 739.8 M | 708.5 M | 645.5 M | 821.7 M | 873.4 M | 817.7 M | 826.4 M | 802.6 M | 492 M |
| WST | 23.5 M | 115.9 M | 136.5 M | 162.4 M | 182 M | 128.6 M | 196.8 M | 228.9 M | 254.8 M | 297.2 M | 419 M | 758.7 M | 763.5 M | 710.9 M | 594.6 M | 584.9 M | 614.1 M |
| SNN | 127.9 M | 862 M | 846 M | 810 M | 749 M | 628 M | 801 M | 934 M | 863 M | 815 M | 295 M | 593 M | 315 M | 425 M | 657 M | 755.5 M | 500.2 M |
| DGX | (601.3 M) | 995 M | 1.2 B | 1.5 B | 983 M | 1.4 B | 1.3 B | 1.2 B | 1.1 B | 1.2 B | 2 B | 2.4 B | 1.4 B | 1.3 B | 1.3 B | 1.6 B | 1.1 B |
Insulet and related stocks such as DexCom Inc, STERIS plc, and Koninklijke Philips Operating Income description
Operating Income is the amount of profit realized from Insulet operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Insulet is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| Insulet | PODD |
| Classification | Obamacare Repeal |
| Business Address | 100 Nagog Park, |
| Exchange | NASDAQ Exchange |
USD 242.74
Check out Insulet Performance and Insulet Correlation. For information on how to trade Insulet Stock refer to our How to Trade Insulet Stock guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Insulet technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.